Soleno Therapeutics Class Action Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy SLNO?
Source: Globenewswire
- Lawsuit Background: Soleno Therapeutics is facing a class action lawsuit due to safety issues related to its DCCR drug, with investors who purchased stock between March 26, 2025, and November 4, 2026, potentially seeking to recover losses.
- Stock Price Volatility: On August 15, 2025, Soleno's stock price dropped 11.98% to $68.09 over two days following a report from Scorpion Capital, indicating market concerns regarding the drug's safety.
- Significant Disclosure: On September 10, 2025, Soleno disclosed that a patient died after taking DCCR, causing the stock price to decline by 19.21% to $56.72 over two days, further exacerbating investor losses.
- Financial Impact: On November 4, 2025, Soleno reported financial results indicating that DCCR's market launch was disrupted, leading to a 26.59% drop in stock price to $46.87, reflecting a severe loss of investor confidence in the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.760
Low
75.00
Averages
110.50
High
125.00
Current: 52.760
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti LLC has initiated a class action lawsuit against Soleno Therapeutics on behalf of investors, alleging that the company failed to disclose critical information between March 26, 2025, and November 4, 2025, resulting in investor losses.
- Allegations Details: The complaint claims that Soleno and certain executives did not disclose safety concerns related to the DCCR clinical trial, including excessive fluid retention among participants, which significantly undermined the commercial viability of DCCR.
- Potential Risks: The undisclosed safety risks associated with DCCR could lead to high patient discontinuation rates, reluctance from prescribers, adverse regulatory actions, and potential reputational damage, thereby increasing the company's legal liabilities.
- Investor Action: Investors affected by the alleged fraud must request to be appointed as lead plaintiff by May 5, 2026, although participation in any recovery does not require serving as lead plaintiff.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26 and November 4, 2025, to apply as lead plaintiffs by May 5, 2026, to potentially receive compensation without any out-of-pocket fees.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety risks associated with its DCCR drug during clinical trials, including issues related to fluid retention in participants, leading to investor losses once the true information was revealed.
- Commercial Viability Risks: The undisclosed safety concerns have materially impacted DCCR's commercial viability, potentially resulting in higher patient discontinuation rates, prescriber reluctance, and adverse legal consequences, thereby exacerbating investor loss risks.
- Counsel Selection Importance: Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record, noting that many firms issuing notices lack the necessary resources and experience to effectively represent investors' interests.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit with a lead plaintiff deadline on May 5, 2026, affecting those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), including serious concerns like excess fluid retention and potential heart failure in children, which could severely impact the company's credibility.
- Misleading Market Performance: While Soleno claimed that the DCCR launch
See More
Class Action Lawsuit Filed Against Soleno Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by May 5, 2026.
- Stock Price Volatility: Following a report from Scorpion Capital on August 15, 2025, labeling Soleno's sole product DCCR as overpriced and potentially unsafe for children, the stock price dropped by 7.41%, closing at $71.63.
- Patient Death Incident: On September 10, 2025, Soleno disclosed a patient death linked to DCCR, causing the stock to plummet by 19.21% over the next two trading sessions, closing at $56.72, highlighting severe market concerns regarding product safety.
- Adverse Reaction Impact: During the earnings call on November 4, 2025, Soleno's CEO revealed an 8% discontinuation rate for DCCR due to adverse effects, stating that the Scorpion report disrupted the product's launch trajectory, leading to a further 26.59% drop in stock price to $46.87.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Soleno Therapeutics and certain officers, aiming to recover damages for investors who purchased securities between March 26, 2025, and November 4, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Legal Basis: The lawsuit alleges that the defendants failed to disclose critical information during the class period, potentially leading to investor losses, indicating serious lapses in the company's disclosure practices that could affect its future market reputation.
- Investor Participation Opportunity: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, highlighting the potential impact of this case on investors and its significance in the legal proceedings.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized investor rights law firm that has recovered hundreds of millions for investors, emphasizing its expertise and successful track record in securities fraud cases.
See More
Soleno Therapeutics Shareholder Notice Issued
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Soleno Therapeutics, encouraging those who purchased SLNO shares between March 26, 2025, and November 4, 2025, to contact the firm regarding potential lead plaintiff status, indicating significant legal risks for the company.
- Safety Concerns Allegations: The lawsuit alleges that Soleno downplayed and concealed safety concerns related to its DCCR product during Phase 3 clinical trials, including issues of excess fluid retention in participants, which could lead to increased health risks for patients.
- Decreased Commercial Viability: As a result of these safety concerns, DCCR's commercial viability is severely impacted, potentially leading to higher patient discontinuation rates, reluctance from prescribers, and adverse regulatory actions, which could further damage the company's reputation.
- Shareholder Action Deadline: Shareholders must register for the class action by May 5, 2026, as failing to do so may affect their rights to claims, highlighting the legal pressure facing the company and the urgency for shareholders to act.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti LLC has initiated a class action lawsuit against Soleno Therapeutics on behalf of investors, alleging that the company failed to disclose critical information between March 26, 2025, and November 4, 2025, resulting in investor losses.
- Allegations Details: The complaint claims that Soleno and certain executives did not disclose safety concerns related to the DCCR clinical trial, including excessive fluid retention among participants, which significantly undermined the commercial viability of DCCR.
- Potential Risks: The undisclosed safety risks associated with DCCR could lead to high patient discontinuation rates, reluctance from prescribers, adverse regulatory actions, and potential reputational damage, thereby increasing the company's legal liabilities.
- Investor Action: Investors affected by the alleged fraud must request to be appointed as lead plaintiff by May 5, 2026, although participation in any recovery does not require serving as lead plaintiff.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26 and November 4, 2025, to apply as lead plaintiffs by May 5, 2026, to potentially receive compensation without any out-of-pocket fees.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety risks associated with its DCCR drug during clinical trials, including issues related to fluid retention in participants, leading to investor losses once the true information was revealed.
- Commercial Viability Risks: The undisclosed safety concerns have materially impacted DCCR's commercial viability, potentially resulting in higher patient discontinuation rates, prescriber reluctance, and adverse legal consequences, thereby exacerbating investor loss risks.
- Counsel Selection Importance: Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record, noting that many firms issuing notices lack the necessary resources and experience to effectively represent investors' interests.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit with a lead plaintiff deadline on May 5, 2026, affecting those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), including serious concerns like excess fluid retention and potential heart failure in children, which could severely impact the company's credibility.
- Misleading Market Performance: While Soleno claimed that the DCCR launch
See More
Class Action Lawsuit Filed Against Soleno Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by May 5, 2026.
- Stock Price Volatility: Following a report from Scorpion Capital on August 15, 2025, labeling Soleno's sole product DCCR as overpriced and potentially unsafe for children, the stock price dropped by 7.41%, closing at $71.63.
- Patient Death Incident: On September 10, 2025, Soleno disclosed a patient death linked to DCCR, causing the stock to plummet by 19.21% over the next two trading sessions, closing at $56.72, highlighting severe market concerns regarding product safety.
- Adverse Reaction Impact: During the earnings call on November 4, 2025, Soleno's CEO revealed an 8% discontinuation rate for DCCR due to adverse effects, stating that the Scorpion report disrupted the product's launch trajectory, leading to a further 26.59% drop in stock price to $46.87.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Soleno Therapeutics and certain officers, aiming to recover damages for investors who purchased securities between March 26, 2025, and November 4, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Legal Basis: The lawsuit alleges that the defendants failed to disclose critical information during the class period, potentially leading to investor losses, indicating serious lapses in the company's disclosure practices that could affect its future market reputation.
- Investor Participation Opportunity: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, highlighting the potential impact of this case on investors and its significance in the legal proceedings.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized investor rights law firm that has recovered hundreds of millions for investors, emphasizing its expertise and successful track record in securities fraud cases.
See More
Soleno Therapeutics Shareholder Notice Issued
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Soleno Therapeutics, encouraging those who purchased SLNO shares between March 26, 2025, and November 4, 2025, to contact the firm regarding potential lead plaintiff status, indicating significant legal risks for the company.
- Safety Concerns Allegations: The lawsuit alleges that Soleno downplayed and concealed safety concerns related to its DCCR product during Phase 3 clinical trials, including issues of excess fluid retention in participants, which could lead to increased health risks for patients.
- Decreased Commercial Viability: As a result of these safety concerns, DCCR's commercial viability is severely impacted, potentially leading to higher patient discontinuation rates, reluctance from prescribers, and adverse regulatory actions, which could further damage the company's reputation.
- Shareholder Action Deadline: Shareholders must register for the class action by May 5, 2026, as failing to do so may affect their rights to claims, highlighting the legal pressure facing the company and the urgency for shareholders to act.
See More
